SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001516551-22-000052
Filing Date
2022-11-23
Accepted
2022-11-23 17:23:50
Documents
13
Period of Report
2022-11-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K skye-20221117.htm   iXBRL 8-K 39678
2 EX-10.1 amendmentandacknowledgemen.htm EX-10.1 33974
  Complete submission text file 0001516551-22-000052.txt   207286

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT skye-20221117.xsd EX-101.SCH 1921
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT skye-20221117_lab.xml EX-101.LAB 22080
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT skye-20221117_pre.xml EX-101.PRE 11526
7 EXTRACTED XBRL INSTANCE DOCUMENT skye-20221117_htm.xml XML 10700
Mailing Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130
Business Address 11250 EL CAMINO REAL, SUITE 100 SAN DIEGO CA 92130 (858) 410-0266
Skye Bioscience, Inc. (Filer) CIK: 0001516551 (see all company filings)

IRS No.: 450692882 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-55136 | Film No.: 221417161
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences